Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Agios Pharm
AGIOCurrent price
27.66 USD
+0.55 USD (+2.03%)
Last closed
25.90 USD
Company
www.agios.com
ISIN
US00847X1046
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 506 337 280 USD
Yield for 12 month
-6.01 %
1Y
3Y
5Y
10Y
15Y
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
54.57 USDP/E ratio
2.26Dividend Yield
–Current Year
+36 498 000 USD
Last Year
+26 823 000 USD
Current Quarter
+10 730 000 USD
Last Quarter
+8 964 000 USD
Current Year
+32 333 000 USD
Last Year
+17 319 000 USD
Current Quarter
+9 470 000 USD
Last Quarter
+8 181 000 USD
Key Figures AGIO
1 year
3 years
5 years
10 years
EBITDA
-420 084 000 USD
Operating Margin TTM
Price to Earnings
2.26
Return On Assets TTM
-20.47 %
PEG Ratio
–
Return On Equity TTM
57.29 %
Wall Street Target Price
54.57 USD
Revenue TTM
36 498 000 USD
Book Value
26.96 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
51.10 %
Dividend Yield
–
Gross Profit TTM
-268 952 992 USD
Earnings per share
11.21 USD
Diluted Eps TTM
11.21 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
1 845.92 %
Dividend Analytics AGIO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History AGIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation AGIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
2.26
Forward PE
2.47
Enterprise Value Revenue
18.33
Price Sales TTM
41.27
Enterprise Value EBITDA
-2.33
Price Book MRQ
0.98
Financials AGIO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators AGIO
For 52 weeks
23.42 USD
62.58 USD
50 Day MA
31.91 USD
Shares Short Prior Month
3 404 434
200 Day MA
41.45 USD
Short Ratio
4.77
Shares Short
3 546 674
Short Percent
6.03 %
BeatStart